Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo maintenance after complete response in advanced ovarian or primary peritoneal cancer
NL-OMON33786Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) comparing Sorafenib with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Jun 2009; status: active, not recruiting.
02
Drugs
sorafenib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON33786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33786.